Apellis Pharmaceuticals, Inc. Cash Flow Statement
APLS / Health Care|11 years of annual SEC 10-K data (FY2015-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 11 fiscal years. All figures from audited SEC 10-K filings.
Apellis Pharmaceuticals, Inc. generated $45M in operating cash flow and $45M in free cash flow in FY2025. Free cash flow margin was 4.5% of revenue.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score -0.60 (distress zone, below 1.8 threshold)
- Negative profit margin: -25.3%
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $22.4M | -$197.9M | -$528.6M | -$652.2M | -$746.4M | -$344.9M | -$304.7M | -$127.5M | -$51.0M | -$27.1M | -$46.5M |
| Depreciation & Amortization | - | - | - | - | - | - | $240.0K | - | - | - | - |
| Operating Cash Flow | $45.3M | -$87.9M | -$594.7M | -$513.7M | -$563.1M | -$160.5M | -$211.1M | -$131.2M | -$46.6M | -$26.0M | -$18.9M |
| Capital Expenditures | $313.0K | $403.0K | $773.0K | $1.5M | $1.1M | $5.4M | $1.7M | - | - | - | - |
| Free Cash Flow | $45.0M | -$88.3M | -$595.5M | -$515.3M | -$564.2M | -$165.9M | -$212.8M | - | - | - | - |
| FCF Margin | 4.5% | -11.3% | -150.2% | -683.2% | -847.7% | -66.2% | - | - | - | - | - |